This Company Is One Of The Best Performers In The Legal Cannabis Market

Cronos Group Inc. (NASDAQ: CRON)

Cronos Group Inc. researches, produces, and sells cannabis products in markets where the use of medicinal cannabis is legalized. Germany and Canada are two of the largest markets for the company.

7 of the Biggest Mistakes People Make When Choosing a Financial Advisor Learn More

The cannabis market is expanding as decriminalization and full legalization movements are growing around the world. Medical cannabis products have been legalized in many jurisdictions.

Cronos group is currently the highest performer amongst the handful of publicly traded companies that are involved in the legal cannabis market. Growth this year has been phenomenal, and more is expected. On the 17thof October 2018, Canada will become the first country in North America to fully legalize cannabis, and Cronos’ existing market presence in the country should allow for more rapid growth.

Cronos grew revenue by 594.18% in their last full fiscal year. With more potential markets emerging, this growth is nowhere near its peak potential. Stock prices today are still affordable, representing an opportunity for investors wanting to get in early on a completely new market.

Key Data:

  • 1 Year Price Growth:                   35%
  • YTD Price Growth:                      08%
  • 3 Month Sock Price Growth:     53%

 

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.

 

The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.

 

 

The reports, research and newsletter are based on current and historical market data, as well as publicly available financial data.They are intended to be a starting point for investors. They do not provide every material fact about a company or industry, nor are they recommendations to buy or sell. The writers and the company make no warranties or representations as to the accuracy of these reports.   You should NOT rely solely upon the information or opinions read in the content. Rather, you should use the content as a starting point for doing independent research on the independent analysis and trading methods in the content. The content is impersonal and does not provide individualized advice or recommendations for any specific reader or individual portfolio. By accessing this website you have agreed to our disclaimers and privacy policy.

 

You May Also Like